A novel urine test to monitor antiretroviral treatment efficacy in HIV patients
| ISRCTN | ISRCTN10430191 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10430191 |
| Secondary identifying numbers | N/A |
- Submission date
- 18/09/2015
- Registration date
- 28/10/2015
- Last edited
- 11/06/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
The human immunodeficiency virus (HIV) is a type of virus known as a retrovirus. HIV attacks and weakens the immune system, making it more difficult for a sufferer to fight infections. It is a highly contagious disease, through bodily fluids such as blood, semen and vaginal fluids. There is currently no cure for HIV, but there are a range of drug treatments that can allow people who are HIV positive to lead a long and full life. Antiretroviral therapy (ART) is the standard treatment for HIV, where at least three different antiretroviral (ARV) drugs are given at the same time. This treatment is very effective at supressing the virus and stopping the development of the disease. When a person has been on ART, the amount of HIV present in the blood (viral load) is reduced. After three to six months of treatment, the viral load should have fallen to undetectable levels (undetectable viral load). Currently, HIV is monitored using regular blood tests to check the viral load. This can cause patients a lot of discomfort however, as well as being time consuming and expensive. Recently, metabonomics analysis has shown promise in diagnosing diseases and monitoring drug therapy. This involves measuring the levels of chemicals that are left over after a drug has been broken down by the body (metabolites). The aim of this study is to see whether testing the amount of metabolites in urine is an effective way of monitoring of ART.
Who can participate?
HIV positive adults, currently on combination antiretroviral therapy, who have had an undetectable viral load on their last two visits to the clinic.
What does the study involve?
Ten urine samples are taken from each of the patients taking part in the study. Five of these samples are taken five days in a row, and then once every two weeks for the five remaining samples. The urine samples are then assessed in the laboratory.
What are the possible benefits and risks of participating?
There is no direct benefit for the patients involved in the study. There are no risks of participating as the urine collection is non-invasive.
Where is the study run from?
Wharfside clinic, St Mary’s Hospital (UK)
When is the study starting and how long is it expected to run for?
October 2015 to December 2020 (updated 11/06/2019, previously: April 2016)
Who is funding the study?
1. Imperial NIHR Biomedical Research Centre (UK)
2. Institute for Translational Medicine and Therapeutics (UK)
Who is the main contact?
Dr Xinzhu Wang
xw906@imperial.ac.uk
Contact information
Scientific
Jefferiss Research Trust Laboratories
Variety Wing D, 2nd Floor, Wright-Fleming Institute
Faculty of Medicine, Imperial College London, St Mary's Campus
London
W2 1PG
United Kingdom
| Phone | +44 20 7594 3909 |
|---|---|
| xw906@imperial.ac.uk |
Study information
| Study design | Single-centre observational trial |
|---|---|
| Primary study design | Observational |
| Secondary study design | Case series |
| Study setting(s) | Hospital |
| Study type | Screening |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Optimising metabonomic analysis to monitor combination antiretroviral therapy efficacy in urine samples from HIV patients |
| Study objectives | The aim of this study is to determine which platform builds the best model for assessing patient stability over a short to moderate period of time. |
| Ethics approval(s) | NRES Committee London - Bromley, 04/09/2015, ref: 15/LO/1584 |
| Health condition(s) or problem(s) studied | Human immunodeficiency virus (HIV) |
| Intervention | Ten sequential samples are taken from each patient over the course of 10 weeks. The intra-patient variability is determined in the metabolic profiling of patients who are stable on ART with undetectable viral load over a short-med period of time using using nuclear magnetic resonance spectroscopy and liquid chromatography mass spectrometry. |
| Intervention type | Other |
| Primary outcome measure | Urine metabonomic profiles will be measured using proton nuclear magnetic resonance spectroscopy and liquid chromatography mass spectrometry on days 1, 2, 3, 4, 5, 15, 29, 43, 57 and 71. |
| Secondary outcome measures | N/A |
| Overall study start date | 01/10/2015 |
| Completion date | 31/12/2020 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 20 |
| Key inclusion criteria | 1. At least 18 years of age 2. HIV positive 3. Currently taking combination antiretroviral therapy 4. Two undetectable viral loads measured in the most recent visits |
| Key exclusion criteria | Persons who lack the capacity to consent |
| Date of first enrolment | 01/10/2015 |
| Date of final enrolment | 01/04/2016 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Praed Street
London
W2 1NY
United Kingdom
Sponsor information
University/education
Joint Research Compliance Office
Imperial College London & Imperial College Healthcare NHS Trust
5th Floor, Lab Block, Charing Cross Hospital
Fulham Palace Road
London
W6 8RF
England
United Kingdom
| Phone | +44 20 3311 0212 |
|---|---|
| gary.roper@imperial.ac.uk | |
"ROR" |
https://ror.org/041kmwe10 |
Funders
Funder type
Research organisation
No information available
Private sector organisation / Universities (academic only)
- Alternative name(s)
- ITMAT
- Location
- United States of America
Results and Publications
| Intention to publish date | 31/12/2020 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Stored in repository |
| Publication and dissemination plan | Publication in a peer-reviewed journal. |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
11/06/2019: The following changes were made to the trial record:
1. The intention to publish date was changed from 31/12/2018 to 31/12/2020.
2. The overall end date was changed from 01/04/2016 to 31/12/2020.
3. The plain English summary was updated to reflect these changes.
31/05/2018: The intention to publish date has been changed from 31/05/2016 to 31/12/2018.
31/05/2018: No publications found, verifying study status with principal investigator.
31/03/2016: Ethics approval information added.
